Compositions and methods for delivering drugs to a vessel wall

Abstract

The invention relates to balloon coatings and their use in delivering drugs via a drug-eluting balloon. The delivery can be, e.g., to a vessel wall.

1 - 34 . (canceled) 
     
     
         35 . A coating comprising:
 (i) from 3% to 35% (w/w) of a compound of formula (I)
   F T —[B—(oligo)] n —B—F T   (I),
 
   
       wherein B is a hard segment formed from hexamethylene diisocyanate, oligo is an oligomeric segment including polytetramethylene oxide, F T  is a polyfluoroorgano group, and n is an integer from 1 to 10; and
 (ii) from 70% to 97% (w/w) crystalline rapamycin macrolide. 
 
     
     
         36 . The coating of  claim 35 , wherein the coating comprises (i) from 5% to 25% (w/w) of the compound of formula (I) and (ii) from 75% to 95% (w/w) crystalline rapamycin macrolide. 
     
     
         37 . The coating of  claim 35 , wherein the coating comprises (i) from 15% to 25% (w/w) of the compound of formula (I) and (ii) from 75% to 85% (w/w) crystalline rapamycin macrolide. 
     
     
         38 . The coating of  claim 35 , wherein the polytetramethylene oxide has a molecular weight of from about 800 Da to 3,000 Da. 
     
     
         39 - 44 . (canceled) 
     
     
         45 . The coating of  claim 35 , wherein the coating has a thickness of from 0.01 to 250 microns. 
     
     
         46 . The coating of  claim 35 , wherein the coating comprises a crystalline rapamycin macrolide concentration of from 1.0 μg/mm 2  to 10.0 μg/mm 2 . 
     
     
         47 . The coating of  claim 46 , wherein the crystalline rapamycin macrolide concentration is from 1.0 μg/mm 2  to 6.0 μg/mm 2 . 
     
     
         48 - 56 . (canceled) 
     
     
         57 . A balloon catheter, wherein at least a portion of the surface of the balloon catheter comprises a coating of  claim 35 . 
     
     
         58 - 61 . (canceled) 
     
     
         62 . A method of delivering a rapamycin macrolide to a vessel surface of a mammal, the method comprising contacting the vessel surface with a coating of  claim 35 . 
     
     
         63 - 75 . (canceled) 
     
     
         76 . The method of  claim 62 , wherein the rapamycin macrolide is selected from sirolimus, zotarolimus, everolimus, temsirolimus, ridaforolimus, umirolimus, and biolimus. 
     
     
         77 . The method of  claim 76 , wherein the rapamycin macrolide is sirolimus.